Presence of the HNK-1 epitope on poly(N-acetyllactosaminyl) oligosaccharides and identification of multiple core proteins in the chondroitin sulfate proteoglycans of brain.
The chondroitin sulfate proteoglycans of brain contain several core proteins bearing HNK-1 antibody epitopes. Endo-beta-galactosidase treatment resulted in the almost complete disappearance of HNK-1 staining of proteoglycan immunoblots, indicating that a significant portion of the 3-sulfated sugar residues recognized by this antibody are present on poly(N-acetyllactosaminyl) oligosaccharides. However, after treatment with chondroitinase ABC followed by endo-beta-galactosidase, several proteoglycan species showed HNK-1 reactivity, presumably due to the presence of this epitope on other oligosaccharides which are both resistant to endo-beta-galactosidase and inaccessible to the antibody in the native proteoglycan. Immunostaining of the endo-beta-galactosidase degradation products after separation by thin-layer chromatography demonstrated that HNK-1 reactivity was confined to a minor population of large oligosaccharides. Only a relatively small portion of the native chondroitin sulfate proteoglycans of brain enter a 6-12% SDS-polyacrylamide gel. However, after treatment of the proteoglycans with chondroitinase ABC (or chondroitinase and endo-beta-galactosidase) in the presence of protease inhibitors, seven bands with molecular sizes ranging from 80 to 200 kDa appear in Coomassie Blue stained gels, and two additional bands with molecular sizes of 67 and 350-400 kDa are apparent in fluorographs of sodium [35S]sulfate labeled proteoglycans. Most of these components probably represent individual proteoglycan species rather than different degrees of nonchondroitin sulfate/keratan sulfate glycosylation of a single protein core, since [35S]methionine-labeled proteins of comparable molecular size were synthesized by an in vitro translation system. These findings suggest that chondroitin sulfate proteoglycans which differ in molecular size and composition may be specific to particular cell types in brain.
Gowda
D C
DC
Department of Pharmacology, New York University Medical Center, New York 10016.
Margolis
R U
RU
Margolis
R K
RK
D000818:Animals; D001921:Brain / Q000276:immunology / Q000378:metabolism; D002807:Chondroitin / Q000031:analogs & derivatives*; D002808:Chondroitin Lyases; D002809:Chondroitin Sulfates / Q000276:immunology / Q000378:metabolism*; D000939:Epitopes / Q000302:isolation & purification; D006026:Glycoside Hydrolases; D066298:In Vitro Techniques; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D009844:Oligosaccharides / Q000276:immunology* / Q000378:metabolism; D011134:Polysaccharides / Q000276:immunology / Q000378:metabolism; D014176:Protein Biosynthesis; D011509:Proteoglycans / Q000276:immunology / Q000378:metabolism*; D051381:Rats; D001616:beta-Galactosidase
D000939:Epitopes; D009419:Nerve Tissue Proteins; D009844:Oligosaccharides; D011134:Polysaccharides; D011509:Proteoglycans; C037199:poly-N-acetyllactosamine; D002807:Chondroitin; D002809:Chondroitin Sulfates; D006026:Glycoside Hydrolases; C026093:keratan-sulfate endo-1,4-beta-galactosidase; D001616:beta-Galactosidase; D002808:Chondroitin Lyases